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(OR = 1.18; 1.13–1.22), high chronic disease scores (CDS
10+: OR = 1.15; 1.10–1.20; CDS 5–9: OR = 1.13
(1.09–1.17). Previous use of gastroprotective agents,
indicative of a history of gastropathy, was negatively
associated with persistency: (OR = 0.92; 0.88–0.95). Age,
gender, dosage at initiation, prescriber’s specialty, and
income level did not inﬂuence persistency. CONCLU-
SION: Persistency beyond three months was higher for
coxibs than for non-selective NSAIDs.
MESSAGES FOR THE HEALTH CARE 
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OBJECTIVES: There is a long-standing debate over the
theory that innovations (including innovative pharma-
ceuticals) are largely funded internally by companies.
Supporters of this theory assert that R&D is ﬁnanced
internally from sales, while opponents argue, that R&D
investment is unrelated to sales. The objective of this
study is to empirically test the internal funding theory for
pharmaceutical R&D and suggest policy implications
based on the results. METHODS: Data for US pharma-
ceutical sales, R&D expenditure, proﬁtability (both series
are for 1980 to 2001), and new chemical entity (NCE)
sales (all NCEs approved from 1988 to 2001) are used in
least squares time series regressions to explain variation
in annual percent change in R&D expenditure. Log-log
regressions are used to model the relationship of the
dependent variable to percent change in annual US phar-
maceutical sales and NCE 3-year future sales. A full
model also is estimated. Linear-log models of percentage
change in pharmaceutical sales are estimated for percent
return on stockholders’ equity, percent 10-year return,
and percent annual return. Series were tested for trends,
and, where appropriate, sensitivity analyses were con-
ducted on models. RESULTS: Empirical evidence from
the analyses support the hypothesis that pharmaceutical
R&D is internally funded from sales. The sales coefﬁcient
was estimated to be 1.2% (p < 0.001) and the coefﬁcient
for NCEs 3-year future sales was 0.4% (p < 0.001). When
a full model is estimated with these variables, the coefﬁ-
cients were virtually unchanged and remained statistically
signiﬁcant. Coefﬁcients for the proﬁtability model were
0.09 for percent return on stockholders’ equity, 0.05 for
10-year return, and 0.04 for annual return. CONCLU-
SIONS: The importance of sales for funding pharmaceu-
tical R&D is demonstrated. Policies detrimental to this
relationship should be expected to cause a shift of R&D
effort from the US or to reduce R&D investment in
general.
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OBJECTIVE: Brand loyalty is an elusive, but sought after
consumer attribute. Loyalty, however, is not clearly
deﬁned; especially for pharmaceuticals that have only
recently been associated with their brands. METHODS:
Brand loyalty was assessed from a national Health care
survey, ﬁelded June 2002 to 30,000 online U.S. adults.
For this analysis, three conditions were chosen to repre-
sent a range of consumer types. Respondents (n = 7,209)
were diagnosed and taking a prescription (Rx) for: de-
pression (20% diagnosed, 51% Rx), gastroesophageal
reﬂux disease (GERD, 10% diagnosed, 64% Rx), and/or
high cholesterol (23% diagnosed, 53% Rx). Loyalty was
evaluated by summing four Health care attitudes: would
ask doctor for prescription; prescription advertising pro-
vides useful information; would ask doctor for speciﬁc
medication; and insist that doctor give brand name med-
ication. Responses were on a 5-point scale: 1 = strongly
disagree and 5 = strongly agree. Final scores ranged from
4–20 (mean = 12, standard deviation = 2.8). Loyalty was
then categorized as low (score 4–9) 18%, moderate
(10–14) 65%, and high (15–20) 16%. RESULTS: Loyal
consumers were younger, with more severe disease and
comorbid illnesses. They sought information frequently
and from more sources. Notably, loyal consumers re-
quested medications more than three times more than
those with low loyalty. Between 9–19% requested one of
their high cholesterol, depression, or GERD medications.
Requesters were more likely to be men. They had posi-
tive, proactive Health care attitudes and sought infor-
mation from a variety of sources. Notably, consumers
who requested medications remained on them up to six
months longer. CONCLUSIONS: There is a small, but
distinct group of pharmaceutical brand loyalists that is
proactive and more likely to request prescription med-
ications. Those who request medications trust doctors’
advice and stay on therapy longer. These are our target
patients. They can be reached through doctors, the inter-
net, and family and friends with the information they
need to make sound Health care decisions.
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OBJECTIVES: To demonstrate the use of bayesian 
decision theory to establish optimal commercial drug
development programmes. METHODS: A probabilistic
model of a drug in development was used to estimate 
the expected net return of alternative development pro-
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grammes. Efﬁcacy data were available from a phase II
trial (n = 40). Based on the predicted distribution of treat-
ment effect arising from a Bayesian analysis of these phase
II data, sets of potential results arising from various phase
III trial designs were simulated. The expected return for
the various trial designs were then estimated considering
both the ﬁxed and variable costs associated with differ-
ent trial designs and assuming that regulatory approval
was conditional on a frequentist hypothesis test of efﬁ-
cacy, reimbursement was conditional on expected cost-
effectiveness, and future sales (conditional on successful
licensing and reimbursement) were also a function of
expected cost-effectiveness. The optimal phase III design
was established and the trade-off between more extensive
phase III research and the likelihood of approval and re-
imbursement was explored. RESULTS: Based on the par-
ticular phase II results considered, a phase III trial was
found to have a positive expected return and further
development with a trial of n = 420 was found to be
optimal. If a lower cost-effectiveness threshold for re-
imbursement was assumed, the optimal decision was to
discontinue development. CONCLUSIONS: Where there
are several potential candidates for further development
and limited resources available the model could be
extended to compare different portfolios of research. The
model could also be used to compare different develop-
ment strategies and to explore the relationship between
the regulatory and re-imbursement environment and the
resulting commercial incentives.
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OBJECTIVES: Patient-reported outcomes (PRO’s) are an
increasingly popular endpoint in clinical trials and out-
comes studies. However, PRO’s do not occur in isolation;
they are ﬁltered through personality and attitudes. This
study deﬁnes attitudinal segments among European
Health care consumers and identiﬁes the clinical impli-
cations. METHODS: Analyses are based on 17,341
responses to questionnaires mailed to adults in France,
Germany, and Great Britain in 2002. Results are weighted
and projected to the national populations of each country,
based on gender, age, and region. Respondents indicated
how strongly they agreed with 18 attitudinal statements,
categorized as: in control of health; faith in physicians;
fatalistism; compliance; experimentation; and informa-
tion seeking. A k-means cluster analysis was performed,
with mean substitution for missing values. The solution
was validated using split samples. Clusters were com-
pared by demographics, health habits, quality of life (SF-
8), and resource use. RESULTS: The analysis yielded a
ﬁve cluster solution. “Traditional” (16%) have faith in
physicians and are not experimental. “Open-Minded”
(25%) are willing to explore both traditional and alter-
native Health care options. “Independent Thinkers”
(19%) make their own Health care decisions. They feel
in control of their health and are experimental. “Health
care Roulette” (22%) are gambling with their health.
They are fatalistic, but still experimental. “Apathetic”
(19%) are not engaged in their Health care. Clusters 
differed by outcomes. “Traditional” and “Independent
Thinkers” experience high physical and mental well-
being. “Open-Minded” are generally in poor physical
health with a high rate of multiple comorbidities. Con-
sistent with their fatalistic attitudes, “Health care
Roulette” and “Apathetic” have the worst health habits
and experience low physical well-being. CONCLU-
SIONS: PRO’s should be interpreted within the context
of the reporting patient’s attitudes. Understanding and
measuring attitudinal complexity should be considered in
designing and interpreting studies of resource use, adher-
ence, and quality of life and in developing programs for
delivery of care.
